Thinking impaired in 60% of COVID-19 survivors

In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the Alzheimer’s Association International Conference.

It is not known whether the impairment, such as forgetfulness and language difficulty, will be progressive, said Gabriel de Erausquin, MD, PhD, a neurologist with the health science center’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. The individuals in the study are over 60 years of age and have been assessed once so far. They will be followed for the next three to five years, Dr. de Erausquin said.

The study is being conducted by Dr. de Erausquin and collaborators from the Alzheimer’s Association-led global Cognitive Neuropsychiatric Sequelae of SARS-CoV-2 (CNS SC2) consortium.

Problems with thinking were seen even in recovered COVID-19 patients who had only a mild cold or respiratory ailment after virus exposure, Dr. de Erausquin said.

The study team also assessed participants for anosmia, loss of the sense of smell. The olfactory bulb, which contains the brain cells that react to smell, is primarily where the COVID-19 virus enters the nervous system, Dr. de Erausquin said.

“Persistent lack of smell is associated with brain changes,” he said. “Once the virus has affected the olfactory bulb and caused effects there – changes that we can see with imaging – then other places in the brain that are connected to it also become abnormal, either in function or structure or both.”

Among the Argentine participants, 78% had recovered from SARS-CoV-2 infection that was confirmed by polymerase chain reaction (PCR) testing. Testing confirmed that the other fourth of volunteers were never infected.

Of the 60% of recovered COVID-19 patients who had cognitive impairment, about one in three had severe cognitive impairment, Dr. de Erausquin said. This could be called “dementia-like syndrome,” because it looks like dementia but may not be persistent or progressive, he said.

People between the ages of 60 and 70 have about a 6% lifetime risk of developing Alzheimer’s disease. The Argentine study population reflects a rate of cognitive impairment that is 10 times higher. “That is worrisome,” Dr. de Erausquin said. “This could be the start of a dementia-related epidemic fueled by this latest coronavirus.”

Hernan P. Zamponi, MSc, Leonardo Juarez-Aguaysol, MD, Gabriela Kukoc, LCP, Maria Eugenia Dominguez, LCP, Belén Pini, LCP, Eduardo G Padilla, MD, Maria Calvó, MD, Silvia Beatriz Molina-Rangeon, MD, Gonzalo Guerrero, MD, Mariana Figueredo-Aguiar, LEd, Emiliano Fumagalli, PhD, Agustín Yécora, MD, Traolach S Brugha, MD, Sudha Seshadri, MD, Heather M. Snyder, PhD, Gabriel A. de Erausquin, MD, PhD, Gabriela Gonzalez-Aleman, LCP, PhD, and the Alzheimer's Association CNS SARS-CoV-2 Consortium.
Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.
Presented at the Alzheimer’s Association International Conference, July 29, 2021

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...